Delayed Puberty in Boys; Clinical and Biochemical Characteristics and Effect of Testosterone Treatment

Completed

• Conditions: Delayed Puberty
• Interventions: Other: retrospective data collection

• Registration Number: NCT02034487
• Lead Sponsor: Rigshospitalet, Denmark

Brief Summary

To evaluate the phenotype and biochemical characteristics of boys referred for delayed puberty, to describe the frequency of associated co-morbidities and diseases, to evaluate the diagnostic criteria and the effect of testosterone treatment.

Detailed Description

Delayed Puberty in Boys; Clinical and biochemical characteristics and effect of testosterone treatment, is a retrospective study in a large case series of Danish boys with delayed puberty.

All boys were referred to the Department of Growth and Reproduction to be evaluated for delayed puberty.

Medical history: Birth length, birth weight, gestational age at birth, medical history (including cryptorchidism and hypospadias), family history of delayed puberty in mother, father and possible siblings.

Physical examination: Pubertal staging according to Tanners classification of boys, genitalia development (G1-G5), pubic hair development (PH1-PH6), axillary hair (yes/no), axillary sweat (yes/no), gynecomastia (yes/no), micropenis (yes/no), height, mother height, father height, target height, weight, BMI, bone age and predicted adult height.

Blood sampling for measurement of hormone levels: Follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin A, inhibin B, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3.

Gonadotropin-releasing hormone stimulation test for measurement of peak FSH and peak LH.

Retrospective DNA analysis looking for common polymorphisms.

If testosterone treatment were initiated, route of administration, dose and duration of treatment were registered.

Study Timeline

• Study Start: 1990-01
• Primary Completion: 2013-02
• Study Completion: 2013-10
• Status Verified: 2014-01
• Study First Submitted: 2014-01-09
• Study First Submitted QC: 2014-01-10
• Last Update Submitted: 2014-01-10
• Study First Posted: 2014-01-13
• Last Update Posted: 2014-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 451

Inclusion Criteria

• All boys identified in the period from January 1990 to February 2013

Exclusion Criteria

• Misclassified (other diagnoses)
• Insufficient data
• Lost to follow up

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Boys with delayed puberty	retrospective data collection	Boys with no signs of puberty by an age that is -2 standard deviation below the population mean.

Primary Outcome Measures

Name	Time	Method
Age at diagnosis in boys with delayed puberty.	At first evaluation	We will evaluate the mean age at diagnosis as well as the age distribution of newly diagnosed boys. These data are compared to age at onset and progression of normal puberty in contemporary healthy Danish boys.

Secondary Outcome Measures

Name	Time	Method
Selected secondary outcomes include clinical, auxological and biochemical parameters and association to specific genetic polymorphisms	At first evaluation and during first 12 months of observation / treatment	Specifically, genital stage, pubic hair stage, axillary hair, axillary sweat, gynecomastia, micropenis, height, mother height, father height, target height, weight, BMI, bone age and predicted adult height. We will evaluate serum levels of follicle stimulating hormone, luteinizing hormone, estradiol, anti-mullerian hormone, sex hormone-binding globulin, testosterone, dehydroepiandrosterone-sulfate, androstenedione, inhibin A, inhibin B, growth hormone, insulin like growth factor-1 and insulin like growth factor binding protein-3. We will evaluate the effect of candidate polymorphisms suspected to affect pubertal timing, e.g. FSHR, FSHB, FGF23, KISS1, NeurokininB, GnRH, GnRH-R, LH, LH-R, GHRd3.

Trial Locations

Locations (1)

Department of Growth and Reproduction, Rigshospitalet; 🇩🇰 Copenhagen, Denmark